Previous close | 180.35 |
Open | 181.00 |
Bid | 181.88 x 1000 |
Ask | 182.26 x 800 |
Day's range | 180.30 - 182.29 |
52-week range | 130.96 - 182.89 |
Volume | |
Avg. volume | 5,680,991 |
Market cap | 322.435B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 66.95 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 6.20 (3.44%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | N/A |
Allergan Aesthetics, an AbbVie (NYSE: ABBV) Company, announces Moving the Needle on Ethics- its collaboration with medical aesthetics experts from around the globe aiming to elevate discussions on ethics in aesthetics. The collection of interviews highlights the need for industry-wide transparency and integrity to meet the expected increase in global demand for aesthetics treatments.
AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory a
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies. Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy. They m